The Korean guideline for cervical cancer screening

Kyung Jin Min, Yoon Jae Lee, Mina Suh, Chong Woo Yoo, Myong Cheol Lim, Jaekyung Choi, Moran Ki, Yong Man Kim, Jae Weon Kim, Jae-Hoon Kim, Eal Whan Park, Hoo Yeon Lee, Sung Chul Lim, Chi Heum Cho, Sung Ran Hong, Ji Yeon Dang, Soo Young Kim, Yeol Kim, Won Chul Lee, Jae Kwan Lee

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass-screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papillomavirus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (Papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The cervical cytology combined with HPV test is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within 10 years (recommendation D).

Original languageEnglish
Pages (from-to)232-239
Number of pages8
JournalJournal of Gynecologic Oncology
Volume26
Issue number3
DOIs
Publication statusPublished - 2015 Jul 1

Fingerprint

Early Detection of Cancer
Uterine Cervical Neoplasms
Cell Biology
Guidelines
Papanicolaou Test
Korea
Mass Screening
Developed Countries
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Min, K. J., Lee, Y. J., Suh, M., Yoo, C. W., Lim, M. C., Choi, J., ... Lee, J. K. (2015). The Korean guideline for cervical cancer screening. Journal of Gynecologic Oncology, 26(3), 232-239. https://doi.org/10.3802/jgo.2015.26.3.232
Min, Kyung Jin ; Lee, Yoon Jae ; Suh, Mina ; Yoo, Chong Woo ; Lim, Myong Cheol ; Choi, Jaekyung ; Ki, Moran ; Kim, Yong Man ; Kim, Jae Weon ; Kim, Jae-Hoon ; Park, Eal Whan ; Lee, Hoo Yeon ; Lim, Sung Chul ; Cho, Chi Heum ; Hong, Sung Ran ; Dang, Ji Yeon ; Kim, Soo Young ; Kim, Yeol ; Lee, Won Chul ; Lee, Jae Kwan. / The Korean guideline for cervical cancer screening. In: Journal of Gynecologic Oncology. 2015 ; Vol. 26, No. 3. pp. 232-239.
@article{9fd41d8838cc4863bcb298f82af2e76a,
title = "The Korean guideline for cervical cancer screening",
abstract = "The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass-screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papillomavirus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (Papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The cervical cytology combined with HPV test is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within 10 years (recommendation D).",
author = "Min, {Kyung Jin} and Lee, {Yoon Jae} and Mina Suh and Yoo, {Chong Woo} and Lim, {Myong Cheol} and Jaekyung Choi and Moran Ki and Kim, {Yong Man} and Kim, {Jae Weon} and Jae-Hoon Kim and Park, {Eal Whan} and Lee, {Hoo Yeon} and Lim, {Sung Chul} and Cho, {Chi Heum} and Hong, {Sung Ran} and Dang, {Ji Yeon} and Kim, {Soo Young} and Yeol Kim and Lee, {Won Chul} and Lee, {Jae Kwan}",
year = "2015",
month = "7",
day = "1",
doi = "10.3802/jgo.2015.26.3.232",
language = "English",
volume = "26",
pages = "232--239",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "3",

}

Min, KJ, Lee, YJ, Suh, M, Yoo, CW, Lim, MC, Choi, J, Ki, M, Kim, YM, Kim, JW, Kim, J-H, Park, EW, Lee, HY, Lim, SC, Cho, CH, Hong, SR, Dang, JY, Kim, SY, Kim, Y, Lee, WC & Lee, JK 2015, 'The Korean guideline for cervical cancer screening', Journal of Gynecologic Oncology, vol. 26, no. 3, pp. 232-239. https://doi.org/10.3802/jgo.2015.26.3.232

The Korean guideline for cervical cancer screening. / Min, Kyung Jin; Lee, Yoon Jae; Suh, Mina; Yoo, Chong Woo; Lim, Myong Cheol; Choi, Jaekyung; Ki, Moran; Kim, Yong Man; Kim, Jae Weon; Kim, Jae-Hoon; Park, Eal Whan; Lee, Hoo Yeon; Lim, Sung Chul; Cho, Chi Heum; Hong, Sung Ran; Dang, Ji Yeon; Kim, Soo Young; Kim, Yeol; Lee, Won Chul; Lee, Jae Kwan.

In: Journal of Gynecologic Oncology, Vol. 26, No. 3, 01.07.2015, p. 232-239.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The Korean guideline for cervical cancer screening

AU - Min, Kyung Jin

AU - Lee, Yoon Jae

AU - Suh, Mina

AU - Yoo, Chong Woo

AU - Lim, Myong Cheol

AU - Choi, Jaekyung

AU - Ki, Moran

AU - Kim, Yong Man

AU - Kim, Jae Weon

AU - Kim, Jae-Hoon

AU - Park, Eal Whan

AU - Lee, Hoo Yeon

AU - Lim, Sung Chul

AU - Cho, Chi Heum

AU - Hong, Sung Ran

AU - Dang, Ji Yeon

AU - Kim, Soo Young

AU - Kim, Yeol

AU - Lee, Won Chul

AU - Lee, Jae Kwan

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass-screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papillomavirus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (Papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The cervical cytology combined with HPV test is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within 10 years (recommendation D).

AB - The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass-screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papillomavirus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (Papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The cervical cytology combined with HPV test is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within 10 years (recommendation D).

UR - http://www.scopus.com/inward/record.url?scp=84937438985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937438985&partnerID=8YFLogxK

U2 - 10.3802/jgo.2015.26.3.232

DO - 10.3802/jgo.2015.26.3.232

M3 - Review article

VL - 26

SP - 232

EP - 239

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 3

ER -

Min KJ, Lee YJ, Suh M, Yoo CW, Lim MC, Choi J et al. The Korean guideline for cervical cancer screening. Journal of Gynecologic Oncology. 2015 Jul 1;26(3):232-239. https://doi.org/10.3802/jgo.2015.26.3.232